Lumos Diagnostics Holdings Limited (LDX.AX)
Lumos Diagnostics Holdings Limited operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.12, up 0.00% on the session, giving a market capitalisation of $108.7M. Its beta of 0.54 implies it has historically moved less than the broad market.
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos Diagnostics Holdings Limited was incorporated in 2018 and is based in Carlsbad, California.
Lumos Diagnostics Holdings Limited is most often compared with the following Healthcare names: